Accessibility Menu
Noveris Health Sciences logo

Noveris Health Sciences(OTC) MYCOF

Current Price$0.80
Market Cap$46.84MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-100%
5 Year-100%
1 Year+471%
1 Month-60%
Noveris Health Sciences last closing stock price
MetricPriceDate
Last closeUSD 0.802026-07-22
Noveris Health Sciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-27.27%USD 1.102026-07-13
1 month-60%USD 2.002026-06-22
3 month-20%USD 1.002026-04-23
Year to date+266.6%USD 0.222025-12-31
1 year+471.43%USD 0.142025-07-22
3 year-88.45%USD 6.932023-07-21
5 year-99.94%USD 1,370.912021-07-23
Since inception-100%USD 19,237.482015-05-08

Noveris Health Sciences Financials at a Glance

Market Cap

$46.84MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$0.00

Net Income (TTM)

CA$1.60M

EPS (TTM)

$1.80

P/E Ratio

0.45

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.80

Volume

1,003

Open

$0.80

Previous Close

$0.80

Daily Range

$0.80 - $0.80

52-Week Range

$0.01 - $2.04

Estimated Earnings Date

May 28, 2026

MYCOF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Noveris Health Sciences

Noveris Health Sciences Inc. is a biotechnology firm focused on the research, development, and clinical evaluation of psilocybin-based products. Established in 2013 and headquartered in Vancouver, Canada, the company aims to innovate within the pharmaceutical industry.

Products and Services
  • Psilocybin-based therapeutic products for mental health
  • Clinical trials to evaluate product efficacy and safety
  • Research partnerships with academic institutions
Growth Outlook
  • Significant interest in psychedelic therapies is driving market potential
  • Ongoing clinical trials may lead to breakthrough treatments
  • Strategic partnerships could enhance research capabilities and funding
Financial Highlights
  • Recent quarterly net income reported at -$1,620,678
  • Trailing twelve months (TTM) P/E ratio stands at 9.80
  • Cash and cash equivalents increased to $2,032,921 in Q1 2026
Noveris Health Sciences Inc. operates in a rapidly evolving sector, with increasing recognition of the therapeutic potential of psilocybin. The company's focus on rigorous clinical evaluation positions it well to capitalize on emerging opportunities in mental health treatment. Recent financial data indicates a challenging yet potentially transformative phase, with significant investments in research and development. The increase in cash reserves suggests a commitment to sustaining operations and advancing clinical trials. As the market for psychedelic therapies expands, Noveris Health Sciences Inc. may play a pivotal role in shaping the future of mental health treatment.
AI Generated • Jun 23, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

3

CEO

Jason W. Birmingham

Website

www.mydecine.com

Headquarters

Vancouver, BC V6E 3C9, CA

MYCOF Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

2.04%

Return on Capital

N/A

Return on Assets

-133249.15%

Earnings Yield

2.22%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$46.84MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

58.55M

Volume

1.00K

Avg. Volume

259.855

Financials (TTM)

Gross Profit

CA$0.00

Operating Income

-CA$497.06K

EBITDA

CA$2.98M

Operating Cash Flow

-CA$284.65K

Capital Expenditure

CA$0.00

Free Cash Flow

-CA$284.66K

Cash & ST Invst.

CA$2.03M

Total Debt

CA$424.27K

Noveris Health Sciences Performance Analysis

Noveris Health Sciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CAD 0N/A
20232023-12-31CAD 0N/A
20242024-12-31CAD 0N/A
20252025-12-31CAD 0N/A
Noveris Health Sciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Noveris Health Sciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CAD -41.08-83.3%
20232023-12-31CAD -25.28-38.5%
20242024-12-31CAD -97.17284.4%
20252025-12-31CAD 1.69N/A
Noveris Health Sciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3095.8%
Q32025-09-3029900.0%
Q42025-12-314195.3%
Q12026-03-31-103.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

CA$0.00

N/A

Gross Profit

CA$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$46.84MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$15.61M

N/A

Employees

3

N/A

Net Income

-CA$1.62M

-442.3%

EBITDA

-CA$321.26K

-103.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

CA$2.03M

+20576.6%

Total Debt

CA$424.27K

-94.0%

Accounts Receivable

CA$0.00

N/A

Inventory

CA$0.00

N/A

Long Term Debt

CA$0.00

N/A

Short Term Debt

CA$424.27K

-94.0%

Return on Assets

-1332.49%

N/A

Return on Invested Capital

4.01%

N/A

Free Cash Flow

-CA$284.52K

-3092.8%

Operating Cash Flow

-CA$284.52K

-3092.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TELIFTelescope Innovations Corp.
$0.32+2.24%
PTKFYPT Kalbe Farma Tbk
$8.62-0.81%
LUFFFHerbal Dispatch Inc.
$0.03+0.00%
BTCYBiotricity, Inc.
$0.10-13.62%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$8.08-0.26%
TQQQProShares Trust - ProShares UltraPro Qqq
$66.13-0.06%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$43.37+0.06%
HBANHuntington Bancshares
$17.25-0.06%

Questions About MYCOF

What is the current price of Noveris Health Sciences?

Noveris Health Sciences is trading at $0.80 per share.

What is the 52-week range for Noveris Health Sciences?

Over the past 52 weeks, Noveris Health Sciences has traded between $0.01 and $2.04.

How much debt does Noveris Health Sciences have?

As of the most recent reporting period, Noveris Health Sciences reported total debt of CA$304.02K.

How much cash does Noveris Health Sciences have on hand?

Noveris Health Sciences reported CA$1.46M in cash and cash equivalents in its most recent financial results.

What is Noveris Health Sciences’s dividend yield?

Noveris Health Sciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services